[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cance].

Authors

Toshinori Yanagawa, Kozo Kataoka, Noriko Yamashita, Tomoko Demachi, Ryota Tanaka, Takeshi Nakamura, Kazuma Ito, Kei Kimura, Masataka Ikeda, Kuniyoshi Tanaka

Published in

Gan to kagaku ryoho. Cancer & chemotherapy. Volume 53. Issue 9. Pages 569-573.

Abstract

Prophylactic administration of systemic antibiotics is widely used to mitigate skin-related adverse events (AEs) during anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC). However, the optimal duration of prophylaxis remains unclear, and prolonged use may increase risks such as hepatotoxicity and reduced efficacy. In this single-center retrospective study, mCRC patients receiving anti-EGFR mAbs and prophylactic minocycline as part of a standardized outpatient skin care program were analyzed. Patients were classified into 2 groups based on minocycline duration: 8 weeks or >8 weeks. The primary endpoint was the incidence of Grade ≥2 skin-related AEs at weeks 8 and 12. Secondary endpoints included specific AE types, liver dysfunction, and risk factor analysis using multivariate logistic and Cox regression models. Seventy-three patients were included (8-week group: n = 24; >8-week group: n = 49). At week 12, the incidence of Grade ≥2 skin-related AEs was significantly lower in the 8-week group (54.2% vs 81.6%, p = 0.013), particularly for paronychia (16.7% vs 42.9%, p = 0.027). The incidence of liver dysfunction was also lower (16.7% vs 40.8%, p = 0.039). Logistic regression identified younger age and prolonged minocycline use as independent risk factors at week 12, while Cox regression showed age ≥65 years increased risk over the treatment period. Limiting prophylactic minocycline administration to 8 weeks may reduce skin-related AEs and hepatotoxicity. Patient age and treatment duration should be considered when optimizing supportive care protocols for anti-EGFR mAbs therapy.

PMID:
42750622
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.